Bing

SEARCH HISTORY

Celgene Corporation CELG, -1.73% today announced that its direct wholly-owned subsidiary, Strix Corporation, has commenced its previously announced tender offer for all outstanding shares of common stock of Receptos, Inc. RCPT, -0.40% at a price of …
Market Watch · 7/28/2015
tender offer
Both Celgene's top- and bottom-line figures are undeniably important, and they'll likely be the immediate catalyst for any stock price move. However, headline figures don't tell you the most important piece of information …
NASDAQ · 7/21/2015
We have highlighted some of the key stats from this just-revealed announcement below: Earnings: Celgene earnings were in line with expectations. Our consensus called for EPS of $1.08 and the company reported EPS of $1.08 (including stock-based …
ZACKS · 7/23/2015
Celgene
There is potential upside of 6.2% for shares of Celgene based on a current price of $131.59 and an average consensus analyst price target of $139.73. The stock should discover initial support at its 50-day moving average (MA) of $118.87 and subsequent ...
Financial News Network Online · ByPeter Chu · 7/27/2015
Bass' first review, on Feb. 10 against an Acorda Therapeutics patent on the Ampyra multiple sclerosis drug, led to a nearly 10 percent drop in the company's stock price. Celgene's patents cover methods to ensure that thalidomide and related cancer drugs ...
CNBC · 7/29/2015
Seattle biotech Juno Therapeutics (Nasdaq: JUNO) is only about two years old, but it has already made biotech history in many ways. All of this success goes against a broader narrative of the difficulties of being a young biotech company in the Puget …
The Business Journal · 7/22/2015
But Cowen analyst Eric Schmidt, see more upside ahead for the stock, raising his price target from $146 to $150. As he writes: We expect CELG shares to outperform based on greater investor appreciation of the company’s improved pipeline and …
Barron's · ByJohanna Bennett · 7/23/2015
Celgene Corporation (CELG) — I covered CELG stock and my other favorite biotech, Gilead Sciences, Inc. (GILD), several times last year. Both turned in stellar performances in 2014, up 34% and 26%, respectively. Both also remain favorites of S&P Capital ...
Investor Place · BySam Collins · 1/7/2015
Celgene Corporation (NASDAQ:CELG) today announced that its direct wholly-owned subsidiary, Strix Corporation, has commenced its previously announced tender offer for all outstanding shares of common stock of Receptos, Inc. (NASDAQ: RCPT) at a …
4 Traders · 7/28/2015
CHICAGO, July 22, 2015 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for FIT, MNKD, CELG, YHOO and ZU. To see what our analysts have discovered about a particular stock, read the InvestorsObserver's PriceWatch Alert by …
Financial Content · 7/22/2015
Critical Alerts
Related Searches

Celgene

Company
Celgene Corporation is an American biotechnology company that manufactures drug therapies for cancer and inflammatory disorders. I…
Celgene Corporation is an American biotechnology company that manufactures drug therapies for cancer and inflammatory disorders. It is incorporated in Delaware and headquartered in Summit, New Jersey. The company's major products are Thalomid, which is approved for the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum, as well as in combination with dexamethasone for patients with newly diagnosed multiple myeloma, and Revlimid, for which the company has received FDA and EMA approval in combination with dexamethasone for the treatment of multiple myeloma patients who have received at least one prior therapy. Revlimid is also approved in the United States for the treatment of patients with transfusion-dependent anemia due to Low- or Intermediate …
Data from: Wikipedia